
About Boryung Pharmaceutical
Boryung Pharmaceutical is a publicly listed company based in Seoul (South Korea) founded in 1963. Finished formulations and APIs are developed for diverse disease areas. The company has 1,650 employees. Boryung Pharmaceutical has completed 1 acquisition, including ViGenCell. Its chief executive, as recorded, is Tae Choi. Its website boryung.co.kr draws about 106 thousand monthly visits. Boryung Pharmaceutical offers products and services including Pharmaceutical Products and Investor Relations Services. Its focus areas include Traditional Pharmaceuticals and Diversified. Its legal entity is Boryung Co., Ltd.
Company details
Boryung Pharmaceutical was established in 1963 and is headquartered in Seoul, South Korea. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) and finished formulations are produced for multiple disease categories. Development activities span various therapeutic areas, supporting drug manufacturing and distribution primarily within the Asian market. Leadership is provided by CEO Tae Choi, overseeing core research and production processes.
- Headquarters Seoul, South Korea
- Employees 1,650
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website boryung.co.kr/en
- Social Facebook
- Legal Name Boryung Corporation
- Annual Revenue$706.27 M (USD)0.03as on Dec 31, 2025
- Net Profit$44.52 M (USD)-7.65as on Dec 31, 2025
- EBITDA$75.19 M (USD)-4.17as on Dec 31, 2025
- Employee Count1,650
- Investments & Acquisitions
Products & Services of Boryung Pharmaceutical
Boryung Pharmaceutical offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Investor Relations Services.
Pharmaceutical drugs and related items are offered by the company in the healthcare sector.
Information on company history and missions is provided to investors through designated platforms.
People of Boryung Pharmaceutical
1 people are tracked at Boryung Pharmaceutical (1 in leadership); the tracked headcount is 1,650.
| Name | Role | Group |
|---|---|---|
Tae Choi | CEO | Leadership |
Complete people profiles for Boryung Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Boryung Pharmaceutical
Boryung Pharmaceutical is a publicly listed company on the KRX with ticker symbol 003850 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Oct 1988
- Listed onKRX: 3850
- Listed entityBoryung Corporation
- Exchange sectorHealth technology
- ISINKR7003850005
- Share price8,360.00 KRW (-0.12% on the day) · 2026-10-14
- Market capitalisation707,101,715,012.00 KRW
- Price to earnings5.8
- EPS (diluted, trailing year)1,434.59 KRW
- Dividend yield1.91%
- Volume (last session)77,032
Financials of Boryung Pharmaceutical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 1,020.00B KRW | 64.30B KRW | 108.59B KRW |
| 2024 | 1,020.00B KRW | 69.63B KRW | 113.32B KRW |
| 2023 | 859.63B KRW | 40.20B KRW | 112.09B KRW |
| 2022 | 760.48B KRW | 41.89B KRW | 93.16B KRW |
| 2021 | 627.28B KRW | 43.04B KRW | 73.52B KRW |
Detailed financial statements for Boryung Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Boryung Pharmaceutical
Boryung Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ViGenCell.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
T-cell therapies for tumor treatment are developed by ViGenCell. | vigencell.com | Seoul, South Korea | 2013 | Aug 2017 | $1.3M |
Complete acquisition details for Boryung Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Boryung Pharmaceutical
3 dated milestones of Boryung Pharmaceutical across 54 years, from founding to its latest funding, stage changes and deals.
- Founded Boryung Pharmaceutical is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires ViGenCell.
Web traffic of Boryung Pharmaceutical
The website of Boryung Pharmaceutical (boryung.co.kr) receives about 106.1K visits a month and ranks #241,973 among all websites worldwide, #174 in Biotechnology and Pharmaceuticals.
- Monthly visits106.1K
▲ 17.5% vs previous month
- Unique visitors18.4K
per month
- Global rank#241,973
among all websites
- Category rank#174
Health · Biotechnology and Pharmaceuticals
- Bounce rate14%
- Pages per visit13.9
- Average visit4 min 42 sec
- DevicesDesktop 65% Β· Mobile 35%
Websites whose visitors overlap most with Boryung Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| sspharm.co.kr | 100% | 5.9K | #1,210,844 | View details | |
| ildong.com | 100% | 79.3K | #344,860 | View details | |
| bukwang.co.kr | 100% | 142.7K | #395,152 | View details | |
| health.kr | 66% | #14,868 | View details | ||
dailypharm.com | dailypharm.com | 62% | #33,384 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 25 similar websites and full traffic analytics for Boryung Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Boryung Pharmaceutical
Complete news archive for Boryung Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Boryung Pharmaceutical
Boryung Pharmaceutical was founded in 1963.
Boryung Pharmaceutical is headquartered in Seoul, South Korea.
Tae Choi is the CEO of Boryung Pharmaceutical, as recorded in our data.
Boryung Pharmaceutical has 1,650 employees.
Annual revenue of Boryung Pharmaceutical is $706.27M as on Dec 31, 2025.
Boryung Pharmaceutical was established in 1963 and is headquartered in Seoul, South Korea. Operations focus on the pharmaceutical sector, where active pharmaceutical ingredients (APIs) and finished formulations are produced for multiple disease categories. Development activities span various therapeutic areas, supporting drug manufacturing and distribution primarily within the Asian market. Leadership is provided by CEO Tae Choi, overseeing core research and production processes.
Boryung Pharmaceutical offers Pharmaceutical Products and Investor Relations Services.
Yes, Boryung Pharmaceutical is publicly traded on KRX under the ticker symbol 003850.
Boryung Pharmaceutical has made 1 acquisition, including ViGenCell.
Boryung Pharmaceutical operates through Boryung Co., Ltd.
The website of Boryung Pharmaceutical receives about 106 thousand visits a month and ranks #241,973 among all websites worldwide.
